daclatasvir/sofosbuvir / Generic mfg. - LARVOL DELTA

HEPEDIAC: Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia (clinicaltrials.gov) - P=N/A | N=21000 | Active, not recruiting | Sponsor: ANRS, Emerging Infectious Diseases | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis C • Infectious Disease • CD4

A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran. (PubMed, Cost Eff Resour Alloc) - "The results showed that GLE/PIB is cost-effective compared with the two common medication regimens in Iran, SOF/DCV and SOF/VEL, consistent with Iran's national willingness-to-pay threshold based on one time the GDP per capita, making it a good treatment option for patients with hepatitis C."

HEOR • Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Resistance-Driven Treatment Failure: A Challenge to HCV Elimination in Pakistan (ISPOR-EU 2025) - "Patients treated with sofosbuvir/velpatasvir had a lower Y93H RAS rate (52%) than those treated with sofosbuvir/daclatasvir (73%). Patients with cirrhosis and subtype 3b have a higher prevalence of NS5A RASs, which contribute to treatment failure. In real-world settings like Pakistan, the presence of these RASs poses challenges for retreatment, potentially leading to increased healthcare costs and delays in achieving national HCV elimination goals."

Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report. (PubMed, Ann Med Surg (Lond)) - "Even though SJS is rare, the possibility that it might have occurred due to sofosbuvir-daclatasvir highlights the need for clinicians to be vigilant while prescribing this regime and educate the patients about the signs and symptoms of SJS. Clinical practices can lower hazards and improve patient safety by implementing these measures."

Journal • Critical care • Hepatitis C • Herpes Simplex • Infectious Disease • Inflammation • Pneumonia • Steven-Johnson Syndrome

The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis. (PubMed, Medicina (Kaunas)) - "Adverse events included one case of acute pancreatitis, six cases of fatigue (17%), five cases of headache (15%), four cases of diarrhea (12%), three cases of nausea (9%), and four cases of insomnia (12%). The combination of sofosbuvir and daclatasvir is effective in patients with HCV undergoing chronic hemodialysis, achieving a 100% SVR rate."

Journal • CNS Disorders • Fatigue • Hepatitis C • Infectious Disease • Inflammation • Insomnia • Pain • Pancreatitis • Sleep Disorder

Safety and efficacy of different therapeutic regimens in Egyptian adults with moderate COVID-19 infection (EVEREST): a real-world retrospective study. (PubMed, Sci Rep) - "Patients were divided into four treatment arms: standard care, sofosbuvir/daclatasvir (sovodak) plus ivermectin, sofosbuvir/ledipasvir (SOF/LED) plus hydroxychloroquine, and SOF/LED plus ivermectin...Our study reveals that most tested antiviral combinations effectively reduced hospitalization days and progressive CT scans. These regimens demonstrated efficacy in treating moderate COVID-19 to prevent disease progression and complications."

Journal • Real-world evidence • Retrospective data • Infectious Disease • Novel Coronavirus Disease

Nationwide evaluation of hepatitis medication prescription patterns and costs in hepatitis B and C care. (PubMed, J Infect Public Health) - "While advancements have been made, gaps in diagnosis, access to care, and insurance coverage impede effective management. The findings emphasize the need for comprehensive public health strategies, including enhanced vaccination, better screening, and wider access to antiviral therapies. Policymakers must focus on improving healthcare infrastructure and public education to achieve the 2030 hepatitis elimination targets."

Journal • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation

LIVERRISK SCORE EFFECTIVELY PREDICTS FIBROSIS PROGRESSION AND MORTALITY IN HCV PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS (UEGW 2025) - "A total of 26(38.2%) patients underwent upper endoscopy, among whom 13(19.11%) had esophageal varices, 2(2.9%) had gastric or gastroesophageal varices (GOV), and 9(13.2%) presented with hypertensive gastropathy.46(75.4%) were treated with Sofosbuvir and Daclatasvir, followed by Sofosvubir and Velpatasvir for 9(14.8%). The LiverRisk score is an accurate tool to predict liver fibrosis and mortality in HCV patients treated with direct acting antivirals."

Clinical • Addiction (Opioid and Alcohol) • Cardiovascular • Cholestasis • Diabetes • Fibrosis • Gastroenterology • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Hypertension • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Portal Hypertension • Thrombocytopenia

Complete response of HCV-associated primary extranodal Diffuse Large B-cell Lymphoma to direct-acting antiviral therapy alone assessed by [ 18 F]FDG PET/CT (EANM 2025) - "The patient received a 12-week course of DAA-based AVT with sofosbuvir and daclatasvir...Conclusion This report demonstrates that DAA-based AVT alone, as a first-line therapy, can induce a complete response in patients with HCV-associated DLBCL. Prospective studies are needed to further evaluate the outcomes of HCV-associated DLBCL treated with DAA-based AVT alone."

Clinical • FDG PET • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatitis C • Hepatology • Indolent Lymphoma • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • BCL2 • BCL6 • CD20 • FCER2 • IRF4 • MME • PAX5

OUTCOMES OF DIRECT ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C PATIENTS WITH PRE-EXISTING HEPATOCELLULAR CARCINOMA (AASLD 2025) - "Patients were administered various DAAs; daclatasvir+asunaprevir, sofosvubir+ribavirin, sofosbuvir+daclatasvir, ledipasvir/Sofosbuvir±ribavirin, ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin, glecaprevir/pibrentasvir, velpatasvir/Sofobuvir ± ribavirin. This study demonstrated that the DAAs achieved favorable treatment outcomes and was well tolerated in CHC patients with pre-existing HCC. HCC tumor stage, presence of viable HCC and ribavirin use was significantly associated with survival."

Clinical • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

Longitudinal Changes in Immune Biomarkers Following Direct-Acting Antiviral Therapy in HIV/HCV-Coinfected Individuals in Indonesia. (PubMed, J Med Virol) - "A prospective study was conducted involving 132 HIV/HCV-coinfected individuals treated with sofosbuvir/daclatasvir for 12 or 24 weeks...DAA therapy was associated with significant reductions in sICAM-1 and sβ2M levels among HIV/HCV-coinfected individuals, irrespective of liver fibrosis stage. These findings highlight the immunomodulatory benefits of DAA therapy across different stages of liver disease in the Indonesian population."

Biomarker • Journal • Fibrosis • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • B2M • CD14 • ICAM1

High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam. (PubMed, J Viral Hepat) - P4 | "PWID with detectable HCV RNA were referred to three public hospitals for a 12-week regimen of generic sofosbuvir/daclatasvir, with ribavirin if cirrhosis, and with CBO support for referral and adherence...Of the 1201 PWID screened with detectable HCV RNA, 1021 were enrolled: 96% male, median age 42 years, 45% HIV-infected, 16% with advanced liver fibrosis, 55% currently injecting, and 71.5% on methadone maintenance therapy (MMT)...High HCV cure rates can be achieved among PWID in LMICs such as Vietnam using a simple model of care, including a pangenotypic generic direct-acting antiviral combination and CBO support. Trial Registration: ClinicalTrials.gov identifier: NCT03537196."

Journal • CNS Disorders • Fibrosis • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Psychiatry

Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study. (PubMed, BMJ Open) - "Considering the high price of the GLE/PIB compared with the available options in Iran, with the introduction of GLE/PIB into Iran's drug list, insurance coverage and appropriate allocation of necessary resources, a reduction in the cost burden because of hepatitis C treatment is expected for individuals and households. Additionally, with a well-regulated market share of existing medications, the optimal treatment choice for patients will be feasible."

HEOR • Journal • Hepatitis C • Infectious Disease • Inflammation

Efficacy of Sofosbuvir-Velpatasvir-Ribavirin Regimen for Retreatment of Chronic Hepatitis C in Patients With Prior DAA Failure: A Retrospective Study From a National Treatment Center. (PubMed, Int J Hepatol) - "In resource-limited settings where second-line DAAs (such as SOF/VEL/VOX) may be unavailable, optimizing first-line treatments is essential...Prior to retreatment, 27 patients had received a 12-week regimen of sofosbuvir and daclatasvir, while only three had been treated with the sofosbuvir-velpatasvir regimen... First-line DAAs are highly effective to treat naïve patients. In the absence of second-line options, retreatment with first-line DAAs (SOF/VEL plus ribavirin) is a viable alternative."

Journal • Retrospective data • Hepatitis C • Infectious Disease • Inflammation

PULMONARY SARCOIDOSIS – MORE THAN MEETS THE EYE (MTS 2025) - "Hepatitis C treatment initiated with Sofosbuvir and Daclatasvir...Mycophenolate Mofetil was started as steroid sparing agent but replaced with Methotrexate due to intolerance...Mosaic attenuation may indicate small airway granulomatous involvement. Therefore, histology and multidisciplinary discussion are very important."

Chronic Cough • Cough • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Musculoskeletal Pain • Ocular Inflammation • Ophthalmology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • Uveitis

An unusual survival for 6.5 years with end-stage hepatitis C related advanced liver cirrhosis following sustained virologic response with direct antiviral agents - A case report from A low-resource setting. (PubMed, Niger Med J) - "She received a six-month course of direct-acting antivirals (DAAs)daclatasvir and sofosbuvir and achieved sustained virologic response...This case underscores the transformative potential of DAAs in improving survival even among severely decompensated HCV-related cirrhotic patients. It highlights the need for expanded access and subsidization of DAAs in low-resource settings, where liver transplantation is not feasible, and emphasizes the role of aggressive, supportive management in bridging the treatment gap."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Fibrosis • Gastroenterology • Hepatic Encephalopathy • Hepatitis C • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Nephrology • Oncology • Portal Hypertension • Renal Disease • Solid Tumor • Transplantation

A decentralized point of service triple prevention and treatment model for hepatitis B, C and HIV in people who inject drugs in South Africa. (PubMed, Int J Drug Policy) - "A comprehensive, simplified and decentralized point of service triple disease prevention and management intervention model demonstrates a feasible approach to improve access for PWID in South Africa to viral hepatitis and HIV care."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Evaluation of hyaluronic acid and type III procollagen peptide as predictors for treatment response to direct-acting antivirals. (PubMed, World J Virol) - "These findings suggested the remarkable role of fibrogensis markers HA and PIIINP in the prediction of hepatitis C virus DAAs treatment response. Multiplying HA with PIIINP values increase the sensitivity to detect treatment success and thus may aim to improve treatment duration and the disease control."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Leading Role of Sofosbuvir/Daclatasvir in Achieving Hepatitis C Elimination in Egypt. (PubMed, J Viral Hepat) - "Additionally, the review underscores the success of local Egyptian pharmaceutical policies in reducing treatment costs and securing access for all infected individuals. The Egyptian experience offers valuable insights into the potential for replicating its success, particularly in other high-burden regions."

Journal • Review • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial. (PubMed, Lancet) - "Sofosbuvir-daclatasvir was non-inferior to sofosbuvir-velpatasvir. High efficacy was seen with novel strategies, which might help to inform approaches to treatment for harder-to-reach populations."

Head-to-Head • Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Treatment options to support the elimination of hepatitis C: an open label, factorial randomised controlled trial (EASL 2025) - "Background and aims: WHO recommends treating Hepatitis C infection with one of three antiviral combinations for 8 to 12 weeks, two of which (sofosbuvir/velpatasvir and sofosbuvir/daclatasvir) are widely used in low-income settings. SOF/DCV is non-inferior to SOF/VEL and is likely to have higher efficacy in this study. High efficacy was seen with three novel strategies that could improve treatment access for harder-to-reach populations."

Clinical • Late-breaking abstract • Fibrosis • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis

Hepatitis C incidence in Pakistan – large scale test and recall analysis shows that infection rates can be reduced by pro-active 'find and treat' programs (EASL 2025) - "The prevalence of HCV in Pakistan is the highest in the world (estimated at 6.8%) and treatment programs with sofosbuvir/daclatasvir are being rolled out nationwide in an effort to eliminate the infection... Assessment of HCV incidence in high prevalence settings by direct assessment is possible, although recall rates are sub-optimal. High intensity treatment programs with domicile based testing and treatment led to low incidence and re-infection rates but rural opportunistic clinics may be associated with higher rates of infections. Effective elimination programs in high prevalence settings will need strategies that have high rates of testing and treatment in defined geographical areas in order to maintain low levels of infection."

Fibrosis • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Results of the national program for the elimination of viral hepatitis in Uzbekistan (EASL 2025) - "Individuals with a positive PCR test were provided with antiviral therapy (Sofosbuvir + Daclatasvir) for 12 weeks without cirrhosis and 24 weeks with cirrhosis, manufactured in the Arab Republic of Egypt... According to the study, the prevalence of HBV in Uzbekistan was 3.1%, while the prevalence of HCV was 3.8%. The lower prevalence of HBV compared to HCV could be attributed to the introduction of HBV vaccination in Uzbekistan in 2000. The low rates of confirmatory quantitative HBsAg were primarily due to the fact that these tests were financially supported by the state."

Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Treatment of genotype 3 chronic hepatitis C infection: age reduces the efficacy of treatment with sofosbuvir and daclatasvir but the reduction is less marked with sofosbuvir and velpatasvir (EASL 2025) - "Efficacy with sofosbuvir/daclatasvir reduces by a modest amount with increasing age in Pakistan. This reduction is less marked but also seen in people with genotype 3 treated with sofosbuvir/velpatasvir in England. This likely reflects the higher rate of cirrhosis and co-morbidity in the elderly."

Clinical • Fibrosis • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Treatment for chronic hepatitis C infection in Pakistan – in a high prevalence country treatment initiation is sub-optimal and may impact elimination programs (EASL 2025) - "The prevalence of HCV in Pakistan is among the highest in the world (estimated at 6.8%) and current treatment programs with sofosbuvir/daclatasvir are being rolled out nationwide in an effort to eliminate the infection... The prevalence of chronic HCV infection remains very high with rates of 6-8%. Despite the availability of free antiviral treatment and incentives to attend for treatment less than 80% commenced treatment and even fewer were able to complete an SVR12 assessment. Information and awareness programs along with appropriate pictorial literature will be required to assist the elimination program in Pakistan."

Fibrosis • Hepatitis C • Hepatology • Infectious Disease • Inflammation